Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OQL-012
- Development stage
- Unknown
- Lead developer
- OnQuality Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
OQL-012 is an investigational drug being developed for the treatment of hand-foot syndrome (also known as palmar-plantar erythrodysesthesia), a common side effect associated with certain cancer therapies, particularly those involving targeted agents. The drug is in development by OnQuality Pharmaceuticals and has reached the IND (Investigational New Drug) application stage. While detailed mechanism of action information is not publicly available, it is classified as a small molecule drug and is intended to address dermatologic toxicities induced by cancer treatments[5]. Its primary indication under investigation is hand-foot syndrome.
Beyond the preview
Go deeper on OQL-012.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OQL-012.